Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

While Biological E has a stock of 20 crore doses of its vaccine Corbevax, Bharat Biotech has 5 crore doses ready of Covaxin

Watch how many crore vaccine doses Indian firms Bharat Biotech, Biological E have ready now | Covid

While Biological E has a stock of 20 crore doses of its vaccine Corbevax, Bharat Biotech has 5 crore doses ready of Covaxin

Amid the sounding of a Covid alert in India, domestic vaccine-makers Bharat Biotech and Biological E Ltd are sitting on a stockpile of 25 crore doses.
While Biological E has a stock of 20 crore doses of its vaccine Corbevax, Bharat Biotech has 5 crore doses ready of Covaxin. This was reported by news agency PTI quoting company officials.
The vaccines are ready to be dispatched.
This comes even as the Union government has cleared Bharat Biotech's nasal vaccine iNCOVACC as a booster dose.
Dr Vikram Paradkar, Executive Vice President (Manufacturing), Biological E, said the firm produced about 30 crore doses of Corbevax in total, abiding by the vaccine manufacturing commitment to the Central government.
In March 2022, Biological E successfully supplied 10 crore doses to the government.
"Currently, we have approximately 20 crore (200 million) doses that are fully tested and ready for supply, as and when we receive orders. Additionally, we manufactured 20 crore doses equivalent of the antigen which will help us ramp up the manufacturing of the Corbevax finished product quickly," Paradkar told PTI.
Also read|<a href="https://www.editorji.com/india-news/india-nasal-vaccine-price-revealed-800-plus-5-gst-for-bharat-biotech-s-incovacc-says-report-1672121485100">India nasal vaccine price: ₹800 at private, ₹325 in govt hospitals, GST extra for Bharat Biotech iNCOVACC</a>
(With PTI inputs)

Biological E Limited on Saturday announced that its COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India (DCGI) as a heterologous booster dose.
A press release from the vaccine maker said the Corbevax can be administered as a booster dose to individuals aged 18 years and above after six months of administration of primary vaccination (two doses) of Covaxin or Covishield vaccines for restricted use in emergency situation.
BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country, it said.
Recently, BE furnished its clinical trials data to the DCGI which after a detailed evaluation and deliberations with Subject Experts Committee, granted their approval for administering Corbevax as a heterologous booster dose to people who have been vaccinated.
BE's clinical trial data showed that its Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective booster.
Mahima Datla, Managing Director, Biological E Limited, said, "We are very happy with this approval, which will address the need for COVID-19 booster doses in India. We have crossed yet another milestone in our COVID-19 vaccination journey. This approval reflects once again the sustained world-class safety standards and high immunogenicity of Corbevax." BE has conducted a multi-centre Phase-III placebo controlled heterologous booster clinical trial in 416 subjects from 18 to 80 years of age who were previously vaccinated with two doses of either Covishield or Covaxin at least six months prior to the administration of Corbevax as a booster, the release added.
Corbevax is entirely developed and manufactured by BE Limited in association with Texas Children's Hospital and Baylor College of Medicine as a recombinant protein sub-unit vaccine against COVID-19.
BE has supplied 100 million doses of the jab to the Central government so far. 

Biological E's Corbevax approved Covid-19 booster dose for 18 and above in India

Biological E Limited on Saturday announced that its Covid-19 vaccine Corbevax has been approved by the Drug Controller General of India  as a heterologous booster dose.

BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country

Biological E Limited on Saturday announced that its COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India (DCGI) as a heterologous booster dose.
A press release from the vaccine maker said the Corbevax can be administered as a booster dose to individuals aged 18 years and above after six months of administration of primary vaccination (two doses) of Covaxin or Covishield vaccines for restricted use in emergency situation.
BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country, it said.
Recently, BE furnished its clinical trials data to the DCGI which after a detailed evaluation and deliberations with Subject Experts Committee, granted their approval for administering Corbevax as a heterologous booster dose to people who have been vaccinated.
BE's clinical trial data showed that its Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective booster.
Mahima Datla, Managing Director, Biological E Limited, said, "We are very happy with this approval, which will address the need for COVID-19 booster doses in India. We have crossed yet another milestone in our COVID-19 vaccination journey. This approval reflects once again the sustained world-class safety standards and high immunogenicity of Corbevax." BE has conducted a multi-centre Phase-III placebo controlled heterologous booster clinical trial in 416 subjects from 18 to 80 years of age who were previously vaccinated with two doses of either Covishield or Covaxin at least six months prior to the administration of Corbevax as a booster, the release added.
Corbevax is entirely developed and manufactured by BE Limited in association with Texas Children's Hospital and Baylor College of Medicine as a recombinant protein sub-unit vaccine against COVID-19.
BE has supplied 100 million doses of the jab to the Central government so far.&nbsp;
Also Watch| <a href="https://www.editorji.com/coronavirus/covaxin-gets-emergency-use-nod-for-6-12-age-group-1650960309414" target="_blank">Covid-19: Covaxin gets emergency use nod for 6-12 age group</a>

India on Wednesday kickstarted Covid vaccination for children in the age group of 12 to 14 years.
Union Health Minister Mansukh Mandaviya had on Monday announced on Twitter that the government was opening up vaccination for 12-14 year old children.
The health minister had also tweeted that the "precaution dose" would be open for all those above 60 years of age. Till now precaution dose was limited to senior citizens suffering from co-morbidities.
Children in the 12 to 14 age group are being administered Biological E's Corbevax. Two doses will be administered at an interval of 28 days. According to news agency PTI, Biological E Ltd has supplied 5 crore doses of Corbevax to the Centre and the vaccine has been distributed to states.
Around 7.11 crore children are expected to be vaccinated in this age group.
The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. The vaccination of frontline workers started from February 2 last year.
The vaccination was opened for above 45 age group from April 1, 2021. The government then decided to expand its vaccination drive by allowing everyone above 18 to be vaccinated from May 1 last year. The next phase of Covid-19 vaccination commenced from January 3 for adolescents in the age group of 15-18 years

Covid vaccination for 12 to 14 age group begins today, precaution dose for all elders

India on Wednesday kickstarted Covid vaccination for children in the age group of 12 to 14 years.
Union Health Minister Mansukh Mandaviya had on Monday announced on Twitter that the government was opening up vaccination for 12-14 year old children.
The health minister had also tweeted that the "precaution dose" would be open for all those above 60 years of age. Till now precaution dose was limited to senior citizens suffering from co-morbidities.
Children in the 12 to 14 age group are being administered Biological E's Corbevax. Two doses will be administered at an interval of 28 days. According to news agency PTI, Biological E Ltd has supplied 5 crore doses of Corbevax to the Centre and the vaccine has been distributed to states.
Around 7.11 crore children are expected to be vaccinated in this age group.

Covid&nbsp;Vaccine:&nbsp;Around 7.11 crore children are expected to be vaccinated in this age group

India on Wednesday kickstarted Covid vaccination for children in the age group of 12 to 14 years.
Union Health Minister Mansukh Mandaviya had on Monday announced on Twitter that the government was opening up vaccination for 12-14 year old children.
The health minister had also tweeted that the "precaution dose" would be open for all those above 60 years of age. Till now precaution dose was limited to senior citizens suffering from co-morbidities.
Children in the 12 to 14 age group are being administered Biological E's Corbevax. Two doses will be administered at an interval of 28 days. According to news agency PTI, Biological E Ltd has supplied 5 crore doses of Corbevax to the Centre and the vaccine has been distributed to states.
Around 7.11 crore children are expected to be vaccinated in this age group.
The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. The vaccination of frontline workers started from February 2 last year.
The vaccination was opened for above 45 age group from April 1, 2021. The government then decided to expand its vaccination drive by allowing everyone above 18 to be vaccinated from May 1 last year. The next phase of Covid-19 vaccination commenced from January 3 for adolescents in the age group of 15-18 years.&nbsp;
Also Watch|&nbsp;<a href="https://www.editorji.com/india-news/biological-e-s-corbevax-is-second-covid-vaccine-approved-for-children-in-india-1645453005861" target="_blank">Biological E's Corbevax is second Covid vaccine approved for children in India</a>

Covid-19 vaccination for children in the age group of 12 -14 years will begin from March 16, Union Health Minister Mansukh Mandaviya informed on Monday.
The health minister also tweeted that the "precaution dose" will also be open for all those above 60 years of age. Till now precaution dose was limited to senior citizens suffering from co-morbidities.
Children in the 12 to 14 age group will be administered Biological E's Corbevax, PTI has reported.
The government decision came after National Technical Advisory Group on Immunization (NTAGI) gave its recommendation to begin vaccination of children in the 12-15 years age group.
The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. The vaccination of frontline workers started from February 2 last year.
The vaccination was opened for above 45 age group from April 1, 2021. The government then decided to expand its vaccination drive by allowing everyone above 18 to be vaccinated from May 1 last year. The next phase of Covid-19 vaccination commenced from January 3 for adolescents in the age group of 15-18 years

India to start Covid-19 vaccination for 12 to 14 age group from March 16

text: Covid&nbsp;jabs for 12-14 age group
Covid-19 vaccination for children in the age group of 12 -14 years will begin from March 16, Union Health Minister Mansukh Mandaviya informed on Monday.
The health minister also tweeted that the "precaution dose" will also be open for all those above 60 years of age. Till now precaution dose was limited to senior citizens suffering from co-morbidities.
Children in the 12 to 14 age group will be administered Biological E's Corbevax, PTI has reported.
The government decision came after National Technical Advisory Group on Immunization (NTAGI) gave its recommendation to begin vaccination of children in the 12-14 years age group.

Covid&nbsp;Vaccination: The "precaution dose" will also be open for all those above 60 years of age now

Covid-19 vaccination for children in the age group of 12 -14 years will begin from March 16, Union Health Minister Mansukh Mandaviya informed on Monday.
The health minister also tweeted that the "precaution dose" will also be open for all those above 60 years of age. Till now precaution dose was limited to senior citizens suffering from co-morbidities.
Children in the 12 to 14 age group will be administered Biological E's Corbevax, PTI has reported.
The government decision came after National Technical Advisory Group on Immunization (NTAGI) gave its recommendation to begin vaccination of children in the 12-15 years age group.
The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. The vaccination of frontline workers started from February 2 last year.
The vaccination was opened for above 45 age group from April 1, 2021. The government then decided to expand its vaccination drive by allowing everyone above 18 to be vaccinated from May 1 last year. The next phase of Covid-19 vaccination commenced from January 3 for adolescents in the age group of 15-18 years
ALSO WATCH:&nbsp;<a href="https://www.editorji.com/coronavirus/india-sees-14-drop-in-daily-new-covid-cases-1644035354616">Covid: India sees 14% drop in new cases</a>

The Drugs Controller General of India has granted restricted emergency use authorisation to Biological E's Covid-19 vaccine Corbevax for the 12 to 18 years age group.
However, the government has not taken a decision yet on vaccinating those aged below 15 years. Currently teens between 15 and 18 years of age are being vaccinated.
Biological E Ltd's Corbevax is the second vaccine to be approved in India for children.
Till now India has been administering Bharat Biotech's Covaxin to teens between 15 and 18 years old since January 3.
Corbevax is being billed as India's first homegrown RBD protein sub-unit vaccine against Covid-19.
The Corbevax vaccine is administered through the intramuscular route with two doses scheduled 28 days apart and is stored at two to eight degrees Celsius temperatures.

Biological E's Corbevax is second Covid vaccine approved for children in India

The Drugs Controller General of India has granted restricted emergency use authorisation to Biological E's Covid-19 vaccine Corbevax for the 12 to 18 years age group.
However, the government has not taken a decision yet on vaccinating those aged below 15 years. Currently teens between 15 and 18 years of age are being vaccinated.
Biological E Ltd's Corbevax is the second vaccine to be approved in India for children.
Till now India has been administering Bharat Biotech's Covaxin to teens between 15 and 18 years old since January 3.
Corbevax is being billed as India's first homegrown RBD protein sub-unit vaccine against Covid-19.

The Drugs Controller General of India has granted restricted emergency use authorisation to Biological E's Covid-19 vaccine Corbevax for the 12 to 18 years age group

The Drugs Controller General of India has granted restricted emergency use authorisation to Biological E's Covid-19 vaccine Corbevax for the 12 to 18 years age group.
However, the government has not taken a decision yet on vaccinating those aged below 15 years. Currently teens between 15 and 18 years of age are being vaccinated.
Biological E Ltd's Corbevax is the second vaccine to be approved in India for children.
Till now India has been administering Bharat Biotech's Covaxin to teens between 15 and 18 years old since January 3.
Corbevax is being billed as India's first homegrown RBD protein sub-unit vaccine against Covid-19.
The Corbevax vaccine is administered through the intramuscular route with two doses scheduled 28 days apart and is stored at two to eight degrees Celsius temperatures.

The Centre has placed an advance order with Hyderabad-based vaccine manufacturer, Biological-E, to reserve 300 million Covid-19 vaccine doses, the health ministry announced on Thursday.
The government said that it would be making an advance payment of ₹1500 crore for the vaccine stock that will be produced between August and December this year. The RBD protein sub-unit vaccine, which is currently undergoing Phase III clinical trials, is likely to be available in the next few months.
The vaccine candidate has been supported by Government of India since the pre-clinical stage. The department of biotechnology had provided a financial assistance of over ₹100 crore to the company.
&nbsp;

Govt buys 300 mn doses of Biological-E’s Covid vaccine in advance

The Centre has placed an advance order with Hyderabad-based vaccine manufacturer, Biological-E, to reserve 300 million Covid-19 vaccine doses

The Centre has placed an advance order with Hyderabad-based vaccine manufacturer, Biological-E, to reserve 300 million Covid-19 vaccine doses, the health ministry announced on Thursday.
The government said that it would be making an advance payment of ₹1500 crore for the vaccine stock that will be produced between August and December this year. The RBD protein sub-unit vaccine, which is currently undergoing Phase III clinical trials, is likely to be available in the next few months.
The vaccine candidate has been supported by Government of India since the pre-clinical stage. The department of biotechnology had provided a financial assistance of over ₹100 crore to the company.
&nbsp;

biological e

Categories